BACKGROUND: The frequency with which patients in Child-Pugh B having hepatocellular carcinoma are treated following the international guidelines according to the Barcelona Clinic Liver Cancer stages is unknown. AIMS: To investigate treatment allocation for Child-Pugh B patients in different tumour stages, with particular interest in the intermediate stage. METHODS: Patients were retrospectively identified from a consecutively collected series. Treatment was carried out primarily according to the guidelines. RESULTS: Of 86 Child-Pugh B patients, 45 were Barcelona early stage, of which the Child-Pugh scores were 46.7% B7, 33.3% B8, 20.0% B9; 27 patients were intermediate stage (B7 59.3%, B8 37.0% and B9 3.7% respectively), 12 were advanced (41.7% B7, 25.0% B8 and 33.3% B9) and 2 were terminal (both B9). In the intermediate stage, transarterial chemoembolization (or ablation) was performed in 68.8% of the Child-Pugh B7 patients, 50% of the B8 patients and 0% of the B9 patients. Median survival of the intermediate patients was 8.0 months (9.0 in B7 vs. 6.0 in -B8/B9, P=0.048). Survival of the intermediate stage patients undergoing chemoembolisation was 22.0 months in Child-Pugh B7 and 6.0 in B8. CONCLUSIONS: Approximately half of the intermediate stage patients can undergo locoregional treatment with good survival when in the Child-Pugh B7. The Child-Pugh numeric score impacts survival, suggesting that this tumour stage be refined.
BACKGROUND: The frequency with which patients in Child-Pugh B having hepatocellular carcinoma are treated following the international guidelines according to the Barcelona Clinic Liver Cancer stages is unknown. AIMS: To investigate treatment allocation for Child-Pugh B patients in different tumour stages, with particular interest in the intermediate stage. METHODS:Patients were retrospectively identified from a consecutively collected series. Treatment was carried out primarily according to the guidelines. RESULTS: Of 86 Child-Pugh B patients, 45 were Barcelona early stage, of which the Child-Pugh scores were 46.7% B7, 33.3% B8, 20.0% B9; 27 patients were intermediate stage (B7 59.3%, B8 37.0% and B9 3.7% respectively), 12 were advanced (41.7% B7, 25.0% B8 and 33.3% B9) and 2 were terminal (both B9). In the intermediate stage, transarterial chemoembolization (or ablation) was performed in 68.8% of the Child-Pugh B7 patients, 50% of the B8 patients and 0% of the B9 patients. Median survival of the intermediate patients was 8.0 months (9.0 in B7 vs. 6.0 in -B8/B9, P=0.048). Survival of the intermediate stage patients undergoing chemoembolisation was 22.0 months in Child-Pugh B7 and 6.0 in B8. CONCLUSIONS: Approximately half of the intermediate stage patients can undergo locoregional treatment with good survival when in the Child-Pugh B7. The Child-Pugh numeric score impacts survival, suggesting that this tumour stage be refined.
Authors: Luciana Kikuchi; Aline Lopes Chagas; Regiane S S M Alencar; Claudia Tani; Marcio A Diniz; Luiz A C D'Albuquerque; Flair José Carrilho Journal: Clinics (Sao Paulo) Date: 2017-08 Impact factor: 2.365
Authors: David P Dorn; Mary K Bryant; Jessica Zarzour; J Kevin Smith; David T Redden; Souheil Saddekni; Ahmed Kamel Abdel Aal; Stephen Gray; Jared White; Devin E Eckhoff; Derek A DuBay Journal: HPB (Oxford) Date: 2014-07 Impact factor: 3.647